References

1Jichlinski P & Leisinger H., Fluorescence Cystoscopy in the Management of Bladder Cancer: A Help for the Urologist!; Urologia Internationalis 2005;74:97-101.
2Frampton JE & Plosker GL., Hexyl Aminolevulinate in the Detection of Bladder Cancer. Drugs 2006;66(4):571-578.
3Babjuk M et al., European Association of Urology. Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS). 2015.
4Witjes JA et al., Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations; European Urology 2010;57:607-614.
5Malmstrom P-U et al., Role of Hexaminolevulinate-Guided Fluorescence Cystoscopy in Bladder Cancer: Critical Analysis of the Latest Data and European Guidance; Scandinavian Journal of Urology and Nephrology 2012;46:108-116.
6Soloway M & Khoury S., Bladder Cancer 2nd International Consultation on Bladder Cancer - Vienna. 2nd ed. ICUD-EAU. 2012.
7Witjes JA., Is Fluorescent Cystoscopy of Cost/Benefit/Therapeutic Value for Carcinoma In Situ of the Bladder?; Journal of Urology 2013;190:19-21.
8Botteman MF et al., The Health Economics of Bladder Cancer - A Comprehensive Review of the Published Literature; Pharmaeconomics 2003;21(18):1315-1330.
9Sangar VK et al., The Economic Consequences of Prostate and Bladder Cancer in the UK; BJU International 2005;95(1):59-63.
10Sievert KD et al., Economic Aspects of Bladder Cancer: What are the Benefits and Costs?; World Journal of Urology 2009;27(3):295-300.
11Stenzl A et al., European Association of Urology. Guidelines on Bladder Cancer Muscle-invasive and Metastatic. 2012.
12Stenzl A et al., Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Non-muscle Invasive Bladder Cancer; Journal of Urology 2010;184(5):1907-1913.
13Grossman HB et al., Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy; Journal of Urology 2012;188(1):58-62.
14Jocham D et al., Improved Detection and Treatment of Bladder Cancer Using Hexaminolevulinate Imaging: A Prospective Phase III Multicenter Study; Journal of Urology 2005;174(3):862-866.
15Hermann GG et al., Fluorescence-Guided Transurethral Resection of Bladder Tumours Reduces Bladder Tumour Recurrence Due to Less Residual Tumour Tissue in Ta/T1 Patients: a Randomized Two-Centre Study; BJU International 2011;108(8Pt2):E297-303.
16Burger M et al., Photodynamic Diagnosis of Non-Muscle-Invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-Analysis of Detection and Recurrence Based on Raw Data. European Urology 2013; 64(5):846-854.
17Fradet Y et al., A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study; Journal of Urology 2007;178:68-73.
19Jichlinski P et al., Hexyl Aminolevulinate Fluorescence Cystoscopy: A New Diagnostic Tool for the Photodiagnosis of Superficial Bladder Cancer—A Multicenter Study; Journal of Urology 2003;170:226-229.
20Schmidbauer J et al., Improved Detection of Urothelial Carcinoma In Situ with Hexaminolevulinate Fluorescence Cystoscopy; Journal of Urology 2004;171:135-138.
21Burgués JP et al., Hexaminolevulinate Photodynamic Diagnosis in Non-Muscle Invasive Bladder Cancer: Experience of the BLUE Group; Actas Urológicas Españolas 2011;35(8):439-445.
22Drăgoescu O et al., Photodynamic Diagnosis of Non-Muscle Invasive Bladder Cancer Using Hexaminolevulinic Acid; Romanian Journal of Morphology and Embryology 2011;52(1):123-127.
23Ray ER et al., Hexylaminolevulinate Photodynamic Diagnosis for Multifocal Recurrent Nonmuscle Invasive Bladder Cancer; Journal of Endourology 2009;23(6);983-988.
24Sagalowsky AI., Editorial comment; Journal of Urology 2012;188(1):62.
25El Khatib S et al., Kinetics, biodistribution and therapeutic efficacy of hexylester 5-aminolevulinate induced photodynamic therapy in an orthotopic rat bladder tumor model. The Journal of Urology 2004; 171: 2013-2017
27Ryan J M et al, Blue-light cystoscopy for detection and treatment of non-mucle invasive bladder Cancer; The Canadian Journal of Urology;19 (2);April 2012
28Zaak D et al., Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues; European Urology. Supplement 2008;7:537-541.
29Witjes JA et al., Comparison of Hexaminolevulinate Based Flexible and Rigid Fluorescence Cystoscopy with Rigid White Light Cystoscopy in Bladder Cancer: Results of a Prospective Phase II Study. European Urology 2005;47:319-322.
30Loidl W et al., Flexible Cystoscopy Assisted by Hexaminolevulinate Induced Fluorescence: A New Approach for Bladder Cancer Detection and Surveillance? European Urology 2005;47:323-326.
31Wong K et al., Treatment of Transitional Cell Cancer of the Bladder Using Out-Patient Flexible Cystoscopy and Photodynamic Assisted Holmium Laser Ablation. EAU 2011; Abstract 537.
32Hermann GG et al., Outpatient Diagnostic of Bladder Tumours in Flexible Cystoscopes: Evaluation of Fluorescence-Guided Flexible Cystoscopy and Bladder Biopsies. Scandinavian Journal of Urology and Nephrology 2012;46:31-36.
33Bertrand J et al., Interest of Flexible Videocystoscopy in Blue Light (+Hexvix®) in Consultation for the Diagnosis of Vesical Tumor [Article in French]. Progrès en Urologie 2012;22:172-177.
34Karl A et al., Flexible Photodynamic Diagnosis of the Bladder – Ready for the Outpatient Setting? Journal of Urology 2014;191:e237–8 [Abstract MP22-09].
35Dindyal S et al., The Economic Benefit of Photodynamic Diagnosis in Non-Muscle Invasive Bladder Cancer. Photodiagnosis and Photodynamic Therapy 2008;5:153-158.
36Gomella LG., Editorial Comment on: a New Generation of Optical Diagnostics for Bladder Cancer: Technology, Diagnostic Accuracy, and Future Applications; European Urology 2009;56(2):296-297.
37Grossman HB et al., A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients with Bladder Cancer; Journal of Urology 2007;178:62-67.
38Geavlete B et al., Treatment Changes and Long-Term Recurrence Rates After Hexaminolevulinate (HAL) Fluorescence Cystoscopy: Does it Really Make a Difference in Patients with Non-muscle-invasive Bladder Cancer (NMIBC)?; BJU International 2012;109(4):549-556.
39Malmstrom P-U et al., Fluorescence-guided Transurethral Resection of Bladder Cancer Using Hexaminolevulinate: Analysis of Health Economic Impact in Sweden; Scandinavian Journal of Urology and Nephrology 2009;43:192-198.
40Otto W et al., Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?; Clinical Medicine. Oncology 2009;3:53-58.
41Garfield SS et al., The Cost-effectiveness of Blue Light Cystoscopy in Bladder Cancer Detection: United States Projections Based on Clinical Data Showing 4.5 Years of Follow Up After a Single Hexaminolevulinate Hydrochloride Instillation; The Canadian Journal of Urology 2013;20(2):6682-6689.
42NHS Technology Adoption Centre (NTAC). How to Why to Guides. Photodynamic Diagnosis of Bladder Cancer. 2011. Available at: http://www.ntac.nhs.uk/HowToWhyToGuides/How-to-Why-to-Guides.aspx (accessed June 2013).
43NHS Technology Adoption Centre (NTAC). The Cost Impact of Implementing Photodynamic Diagnosis of Non-Muscle Invasive Bladder Cancer in England. Final Report. May 2011. Available at: http:/ntac.nhs.uk/web/files/casestudies/case_study_-_pdd.pdf (accessed June 2013).
44Ploeg M et al., The Present and Future Burden of Urinary Bladder Cancer in the World; World Journal of Urololgy 2009;27:289-293.
45Cheng L et al., Bladder Cancer: Translating Molecular Genetic Insights into Clinical Practice; Human Pathology 2011;42:455-481.
46Wong JT et al., Bladder Squamous Cell Carcinoma; Radiographics 2004;24:855-860.
47NCI: Bladder Cancer. Available at: http://www.cancer.gov/cancertopics/types/bladder (accessed June 2013).
48Puente D et al., A Pooled Analysis of Bladder Cancer Case-Control Studies Evaluating Smoking in Men and Women; Cancer Causes & Control 2006;17:71-79.
49Freedman ND et al., Association Between Smoking and Risk of Bladder Cancer among Men and Women; JAMA 2011;306:737-745.
50Samanic C et al., Occupation and Bladder Cancer in a Hospital-Based Case-Control Study in Spain; Occupational and Environmental Medicine 2008;65:347-353.
51Garcia-Closas M et al., NAT2 Slow Acetylation, GSTM1 Null Genotype, and Risk of Bladder Cancer: Results from the Spanish Bladder Cancer Study and Meta-Analyses; Lancet 2005;366:649-659.
52Cárdenas-Turanzas M et al., Comparative Outcomes of Bladder Cancer; Obstetrics and Gynecology 2006;108:169-175.
53Nieder AM et al., Radiation Therapy for Prostate Cancer Increases Subsequent Risk of Bladder and Rectal Cancer: A Population Based Cohort Study; Journal of Urology 2008;180:2005-2009.
54Travis LB et al., Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's Lymphoma; Journal of the National Cancer Institute 1995;87:524-530.
55Steinmaus CM et al., Diet and Bladder Cancer: A Meta-Analysis of Six Dietary Variables; American Journal of Epidemiology 2000;151:693-702.
56American Cancer Society. Cancer Facts & Figures 2011. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
57Sylvester RJ et al., Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials; European Urology 2006;49:466-467.
58Bordier B et al., Photodynamic Diagnosis in Non-Muscle Invasive Bladder Cancer; European Urology Supplement 2010:9:411-418.
59Brausi M et al., Variability in the Recurrence Rate at First Follow-Up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC Studies; European Urology 2002;41:523-531.
60Herr HW., Quality control in transurethral resection of bladder tumours; BJU International 2008;102:1242-1246.
61Herr HW., The Value of a Second Transurethral Resection in Evaluating Patients with Bladder Tumors; Journal of Urology 1999;162:74-76.
62Hollenbeck BK et al., Risk Factors for Adverse Outcomes after Transurethral Resection of Bladder Tumors; Cancer 2006;106:1527-1535.
63Burger M et al., Calculating the Price of a New Diagnostic or Therapeutic Option. Example of Transurethral Resection of Bladder Tumors Using Photodynamic Diagnostics with Hexaminolevulinic Acid [Article in German]. Urologe A 2008;47:1239-1244.
64NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 1.2013. Available at: http://www.nccn.org/. (accessed June 2013).
65Pawinski A et al., A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer; Journal of Urology 1996;156:1934-1940.
66 NICE. Bladder Cancer: Diagnosis and Management. NICE guidelines NG2. Available at: http://www.nice.org.uk/guidance/ng2/.
67Witjes JA et al., Clinical and Cost Effectiveness of Hexaminolevulinate-Guided Blue-Light Cystoscopy: Evidence Review and Updated Expert Recommendations; European Urology 2014; 66(5):863-871.
68Daneshmand S et al., Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Appropriate Use in the USA; Nature Reviews Urology 2014;11(10):589-596.
69Stenzl A et al., Detection and Clinical Outcome of Urinary Bladder Cancer with 5-Aminolevulinic Acid-Induced Fluorescence Cystoscopy: A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial. Cancer 2011;117:938-947.
70Stein JP et al., Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. Journal of Clinical Oncology 2001;19:666-675.
71Soloway M & Khoury S, Bladder Cancer 2nd International Consultation on Bladder Cancer – Vienna; ICUD-EAU 2012.
72National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Bladder Cancer Version 1; 2015.
73Zare R et al., Blue Light Flexible Cystoscopy in Bladder Cancer in an Outpatient Setting (Video Case Examples). EAU 2015; Abstract V39.
74Dansk BlæreCancer Gruppe, Nationale Kliniske Retningslinier for Behandling af Blæretumorer i Danmark; Dansk Urologisk Selskab 2015. See pdf here
75Pfister C et al., Recommandations en Onco-Urologie 2013 du CCAFU: Tumeur Urothéliales; Progrès en Urologie 2013;23(Suppl 2):S105–S125.
76Associazione Italiana di Oncologia Medica (AIOM), Linee Guida: Carcinoma della Vescica; 2014.
77Helsedirektoratet, Nasjonalt Handlingsprogram med Retningslinjer for Diagnostikk, Behandling og Oppfølging av Blærekreft; 2013. See pdf here
78Regionala Cancercentrum i Samverkan, Cancer i Urinblåsa, Njurbäcken, Urinledare och Urinrör: Nationellt Vårdprogram; 2015. See pdf here
79Marteau F et al., Cost-Effectiveness of the Optical Imaging Agent Hexaminolevulinate for Patients Undergoing Initial Transurethral Resection of Non-Muscle Invasive Bladder Cancer Tumours, European Urology Supplements 2013;12:125.
80Bennison C et al., How Investment in a Hexaminolevulinate (HAL) Technology Would Be Beneficial to Patients and Healthcare Systems in Non-Muscle Invasive Bladder Cancer (NMIBC) in Italy, 10th Health Technology Assessment International Annual Meeting; June, 2013.
82Mowatt G et al., Photodynamic Diagnosis of Bladder Cancer Compared with White Light Cystoscopy: Systematic Review and Meta-Analysis; International Journal of Technology Assessment in Health Care 2011;27(1):3-10.
83Draga RO et al., Photodynamic Diagnosis (5 Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette-Guérin Immunotherapy and Mitomycin C Intravesical Therapy; European Urology 2010;57(4):655-660.
84Yuan H et al., Therapeutic Outcome of Fluorescence Cystoscopy Guided Transurethral Resection in Patients with Non-Muscle Invasive Bladder Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2013;8:e74142.
85 Rose JB et al., Budget Impact of Incorporating One Instillation of Hexaminolevulinate Hydrochloride Blue-Light Cystoscopy in Trans-Urethral Bladder Tumour Resection for Non-Muscle Invasive Bladder Cancer Patients in Sweden. BJU International 2015;epub ahead of print.
86 Mariappan P et al., Real-Life Experience: Early Recurrence with Hexvix Photodynamic Diagnosis–Assisted Transurethral Resection of Bladder Tumour (TURBT) vs Good-Quality White Light TURBT in New Non–Muscle-Invasive Bladder Cancer. Urology 2015;86(2):327-31.
87 Lykke MR et al., Reducing Recurrence in Non-Muscle-Invasive Bladder Cancer Using Photodynamic Diagnosis and Immediate Post-Transurethral Resection of the Bladder Chemoprophylaxis. Scandinavian Journal of Urology 2015;49:230-236.
88 Gakis G et al., Fluorescence-Guided Bladder Tumour Resection: Impact on Survival After Radical Cystectomy. World Journal of Urology 2015;33(10):1429-37.
89 Sfetsas K., Mitropulos D: Reducing understaging of bladder cancer with the aid of photodynamic cystoscopy. J Egyptian Nat Cancer Inst (2016), article in press.
90 Sam S. Chan et al., Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline 2016